TCGX Acquisition to merge with TriGemX Bio and take it public on Nasdaq as TriGemX Bio, Inc.

• Transaction structure includes concurrent $160 million PIPE financing supporting TriGemX Bio's transition to public markets.
• Deal implies approximately $600 million post-transaction equity value for the combined company, assuming no redemptions.

https://finviz.com/stock?t=TCGX&p=d